Global Dermatophytic Onychomycosis Market Growth (Status and Outlook) 2024-2030

Global Dermatophytic Onychomycosis Market Growth (Status and Outlook) 2024-2030

Dermatophytic onychomycosis is a fungal infection of the nail plate, nail bed, and, in some cases, the skin surrounding the nail plate. It is caused by yeast, dermatophytes, and molds; dermatophytes account for 90% of all cases. The fungus, especially Trichophyton rubrum, Trichophyton mentagrophytes, and Epidermophyton floccosum, infects the skin, hair, or nails. It is often perceived by people to be an active and contagious infection. Onychomycosis may persist or worsen if not treated. The fungi that cause onychomycosis exist in common sites such as floors, soil, socks, and shoes. Therapies for onychomycosis include debridement and drugs. Debridement is time consuming and minimally effective in eradicating the fungal infection. Systemic drug treatment is most effective in treating onychomycosis.

The global Dermatophytic Onychomycosis market size is projected to grow from US$ million in 2023 to US$ million in 2030; it is expected to grow at a CAGR of % from 2024 to 2030.

LPI (LP Information)' newest research report, the “Dermatophytic Onychomycosis Industry Forecast” looks at past sales and reviews total world Dermatophytic Onychomycosis sales in 2023, providing a comprehensive analysis by region and market sector of projected Dermatophytic Onychomycosis sales for 2024 through 2030. With Dermatophytic Onychomycosis sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Dermatophytic Onychomycosis industry.

This Insight Report provides a comprehensive analysis of the global Dermatophytic Onychomycosis landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Dermatophytic Onychomycosis portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Dermatophytic Onychomycosis market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Dermatophytic Onychomycosis and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Dermatophytic Onychomycosis.

Factors such as the rising prevalence of dermatophytic onychomycosis, heavy investments to develop therapies, and frequent product innovations will aid in the steady growth of this market during the forecast period. An important factor that will impel the prospects for growth in this market is the augmented focus on combination therapies. Recently, it has been observed that a combination of topical and systemic treatment increases the cure rate when compared to individual therapies. Since combination therapies have improved clinical efficiency and are more cost-effective than terbinafine, they are increasingly being preferred over individual terbinafine-based therapies as they have a higher cure rate.

This report presents a comprehensive overview, market shares, and growth opportunities of Dermatophytic Onychomycosis market by product type, application, key players and key regions and countries.

Segmentation by type
Oral Medicine
External Medicine

Segmentation by application
Age Under 18
Age 18-50
Age Above 50

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Johnson & Johnson
GSK
Novartis
Pfizer
Bausch Health
Kaken Pharmaceutical
Galderma
Sanofi
Allergan
Merz Pharma
Xiuzheng Pharmaceutical
Letai
Qilu Pharmaceutical

Please note: The report will take approximately 2 business days to prepare and deliver.